Roivant Sciences Ltd. (ROIV)
Roivant Sciences Ltd. (ROIV) Stock Price, Analysis & Data
| Bid | 33.49 |
| Market Cap | 26.17B |
| Revenue (ttm) | 7.53M |
| Net Income (ttm) | -266.25M |
| Beta | 1.13 |
| EPS (ttm) | -0.47 |
| PE Ratio (ttm) | n/a |
| Forward PE | -21.09 |
| P/B (ttm) | 5.76 |
| P/S (ttm) | 3474.00 |
| Earnings Date | Nov 9, 2026 |
| Ask | 38.71 |
| Volume | 2,365,761 |
| Avg. Volume (20D) | 6,020,914 |
| Open | 35.22 |
| Previous Close | 35.25 |
| Day's Range | 35.22 - 36.50 |
| 52-Week Range | 11.54 - 37.00 |
| Analyst | Strong Buy |
| Price Target | 41 (13.17%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About ROIV
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease; n...
Financial Performance
In 2026, Roivant Sciences's revenue was 8.26M, a decrease of -71.57% compared to the previous year's 29.05M. Earnings were -299.77M, an increase of 74.3%.
Financial StatementsAnalyst Forecast
According to 11 analyst ratings, the average rating for ROIV stock is "Strong Buy". The 12-month stock price forecast is 41, which is upside of 13.17% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
